Loading...
An Exposure-Response Perspective on the Clinical Dose of Pretomanid
Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intolerant or nonresponsive multidrug-resistant tuberculosi...
Na minha lista:
| Udgivet i: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Microbiology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7927811/ https://ncbi.nlm.nih.gov/pubmed/33077660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01121-20 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|